Chung Yu's questions to Evaxion Biotech A/S (EVAX) leadership • Q2 2024
Question
On behalf of Chung Yu from Ladenburg Thalmann, an associate asked for specifics on the upcoming ESMO data for EVX-01, its potential impact on partnerships, the status of the EVX-B3 collaboration with MSD, and details about the new EDEN 5.0 AI model.
Answer
CSO Birgitte Rono confirmed the ESMO presentation will include a 1-year clinical readout and biomarker analysis. CEO Christian Kanstrup affirmed that positive data would be very important for advancing partnership talks. Rono and Kanstrup also noted the EVX-B3 collaboration with MSD is on track to conclude its first phase in H2 2024. Kanstrup detailed that the upgraded EDEN 5.0 model features enhanced predictive capabilities and will be applied to future internal and partnered programs.